(Albany, New York) – October 14, 2026 – The market dynamics for chronic wounds are witnessing steady growth driven by the Rising Prevalence of Chronic Diseases, Increasing Geriatric Population, Advancements in Advanced Wound Care Products, and Growing Demand for Effective Wound Healing Solutions. Additionally, the development of emerging therapies such as ON101 (Oneness Biotech), TTAX01 (BioTissue), and others will further influence the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Chronic Wounds Market Insights, Epidemiology, and Market Forecast 2034.” This comprehensive report provides an in-depth understanding of chronic wounds, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Key Takeaways from the Chronic Wounds Market

• The chronic wounds treatment market across the 7MM was valued at approximately USD 9,000 million in 2023, according to DelveInsight’s analysis.

• The chronic wounds market is anticipated to grow significantly during the forecast period of 2024–2034, supported by the increasing prevalence of chronic conditions and advancements in wound care technologies. The exact forecast market value and CAGR are not disclosed on the public report page.

• The United States accounted for the largest chronic wounds treatment market size in the 7MM in 2023, representing approximately USD 6,000 million.

• DelveInsight’s analysis indicates that approximately 12 million diagnosed prevalent cases of chronic wounds were reported across the 7MM in 2023.

• The United States accounted for approximately 7 million diagnosed prevalent cases in 2023.

• Among the US chronic wound cases in 2023, pressure ulcers accounted for approximately 38%, diabetic foot ulcers for 35%, venous ulcers for 18%, and other chronic wound types for the remaining 9%.

• Among the EU4 countries and the UK, Germany had the highest diagnosed prevalent population, followed by France and the United Kingdom.

• In Japan, approximately 924,000 diagnosed prevalent cases of chronic wounds were estimated in 2023, with pressure ulcers representing the largest type-specific patient group.

• Leading chronic wound companies, such as BioTissue, PolarityTE, RHEACELL GmbH & Co. KG, Smith & Nephew, Kaken Pharmaceutical, MediWound, Oneness Biotech, Anterogen, and others, are developing products and therapies that may influence the chronic wounds market in the coming years.

• Promising emerging therapies covered in the report include ON101 (Oneness Biotech) and TTAX01 (BioTissue), alongside other developing wound care technologies and treatment approaches.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/chronic-wounds-market-report

Key Factors Driving the Chronic Wounds Market

Rising Prevalence of Chronic Diseases: Increasing cases of diabetes, obesity, peripheral vascular disease, and other chronic conditions contribute to the growing burden of non-healing wounds. Diabetes can impair circulation and wound healing, while vascular disorders may limit oxygen and nutrient delivery to damaged tissues. These factors increase demand for effective wound management products, specialized dressings, and advanced treatment options.

Increasing Geriatric Population: The growing elderly population is contributing to the demand for chronic wound care. Older adults are more susceptible to pressure ulcers, venous ulcers, and wounds associated with reduced mobility, impaired circulation, and other comorbidities. As the population ages, healthcare providers require effective wound prevention, diagnosis, and management strategies to reduce complications and improve patient outcomes.

Advancements in Advanced Wound Care Products: Developments in bioengineered skin substitutes, advanced wound dressings, negative pressure wound therapy (NPWT), and biologic treatments are expanding the treatment landscape. These technologies support wound bed management, infection control, moisture balance, and tissue repair. Growing interest in smart wound dressings and digital wound monitoring may further improve wound assessment and care coordination.

Chronic Wounds Competitive Landscape

Several chronic wound treatments and products are available or under development, including Regranex (becaplermin), Fiblast (trafermin), ON101 (Oneness Biotech), and TTAX01 (BioTissue).

These approaches target different aspects of wound healing. Becaplermin is a recombinant platelet-derived growth factor used for specific diabetic neuropathic ulcers as an adjunct to standard wound care. Trafermin is a recombinant basic fibroblast growth factor used in wound treatment in Japan. ON101 is a botanical ointment developed to support diabetic wound healing by influencing inflammation and tissue repair. TTAX01 is an investigational cryopreserved human umbilical cord tissue product being studied for complex, non-healing diabetic foot ulcers.

The competitive landscape also includes advanced dressings, bioengineered skin substitutes, wound debridement technologies, and negative pressure wound therapy. Product differentiation depends on clinical evidence, wound closure rates, safety, ease of use, cost-effectiveness, reimbursement, and suitability for different wound types.

Discover more about therapies and products set to influence the chronic wounds market @ Chronic Wounds Treatment Landscape

Recent Developments in the Chronic Wounds Market

• In September 2025, Kane Biotech Inc. announced the completion of its US FDA 510(k) submission for revyve Antimicrobial Wound Cleanser, the third product in its revyve line. The product is designed to cleanse acute and chronic wounds and help reduce bacterial load.

• Oneness Biotech’s ON101 has been developed as a botanical ointment for diabetic wound healing. The therapy has been marketed as FESPIXON in Taiwan since June 2021 and received US FDA Fast Track designation in March 2021, according to DelveInsight’s report.

• BioTissue’s TTAX01 is being investigated for complex, non-healing diabetic foot ulcers. The development program includes planned multicenter Phase III trials designed to evaluate wound closure and the safety of treatment in patients with high-risk ulcers.

What are Chronic Wounds?

Chronic wounds are wounds that fail to heal within the expected timeframe, often remaining unhealed after four to six weeks. Unlike acute wounds, which generally progress through an orderly healing process, chronic wounds may remain in a prolonged inflammatory state and are frequently associated with underlying medical conditions.

Common types include diabetic foot ulcers, venous leg ulcers, arterial ulcers, and pressure ulcers. These wounds may develop due to impaired circulation, diabetes-related complications, sustained pressure, reduced mobility, or other factors that interfere with normal tissue repair.

Common signs and symptoms include persistent pain, swelling, redness, drainage, discoloration of surrounding skin, delayed wound closure, and signs of infection. Some wounds may deepen or enlarge if the underlying cause is not adequately addressed.

Diagnosis typically involves a detailed physical examination and assessment of wound location, size, depth, tissue condition, drainage, and surrounding skin. A patient’s medical history is also important, particularly the presence of diabetes, peripheral vascular disease, immobility, or previous wound-healing complications.

Treatment generally focuses on managing the underlying cause, removing nonviable tissue when appropriate, controlling infection, maintaining an appropriate wound environment, and supporting tissue repair.

Chronic Wounds Epidemiology Segmentation

The Chronic Wounds epidemiology section provides insights into the historical and current chronic wound patient pool and forecasted trends for the leading markets. The chronic wounds market report provides epidemiological analysis for the study period 2020–2034 across the leading markets, segmented into:

• Total Diagnosed Prevalent Cases of Chronic Wounds

• Type-specific Diagnosed Prevalent Cases of Chronic Wounds

• Diagnosed Prevalent Cases of Diabetic Foot Ulcers

• Diagnosed Prevalent Cases of Pressure Ulcers

• Diagnosed Prevalent Cases of Venous Ulcers

• Diagnosed Prevalent Cases of Other Chronic Wounds

Scope of the Chronic Wounds Market Report

• Therapeutic Assessment: Current marketed treatments, wound care products, and emerging therapies for chronic wounds

• Chronic Wounds Market Dynamics: Key market forecast assumptions, emerging therapies, advanced wound care products, and market outlook through 2034

• Key Companies: BioTissue, PolarityTE, RHEACELL GmbH & Co. KG, Smith & Nephew, Kaken Pharmaceutical, MediWound, Paracrine, Oneness Biotech, Anterogen, TR Therapeutics, and others

• Key Therapies and Products: Regranex (becaplermin), Fiblast (trafermin), ON101, TTAX01, advanced wound dressings, skin substitutes, and negative pressure wound therapy

• Competitive Intelligence Analysis: SWOT analysis, product assessment, and competitive landscape evaluation

• Unmet Needs, KOLs’ Views, Analyst Insights, Chronic Wounds Market Access, and Reimbursement

To know more about chronic wound companies working in the treatment market, visit @ Chronic Wounds Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chronic Wounds Market Report Introduction

2. Executive Summary for Chronic Wounds

3. SWOT Analysis of Chronic Wounds

4. Chronic Wounds Patient Share (%) Overview at a Glance

5. Chronic Wounds Market Overview at a Glance

6. Chronic Wounds Background and Overview

7. Chronic Wounds Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Wounds

9. Chronic Wounds Current Treatment and Medical Practices

10. Chronic Wounds Unmet Needs

11. Chronic Wounds Emerging Therapies

12. Chronic Wounds Market Outlook

13. Country-Wise Chronic Wounds Market Analysis (2020–2034)

14. Chronic Wounds Market Access and Reimbursement of Therapies

15. Chronic Wounds Market Drivers

16. Chronic Wounds Market Barriers

17. Chronic Wounds Appendix

18. Chronic Wounds Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/